Objective: To describe the postoperative clinical outcomes of patients with right ventricular dysfunction and pulmonary hypertension who undergo mitral valve replacement surgery.Methodology: Descriptive, longitudinal, retrospective study.Patients older than 18 years, who underwent mitral valve replacement between June 2013 and May 2021, were included.The information was obtained retrospectively based on the electronic medical record of each patient.Right ventricular dysfunction was defined by the presence of TAPSE (Tricuspid Annular Plane Systolic Excursion) < 17 mm and pulmonary hypertension by the presence of a pulmonary artery systolic pressure > 35 mmHg.Results: 194 patients were included in the study.The median age was 60 years (IR 51-69 years) and 63% were female.The prevalence of right ventricular dysfunction and pulmonary hypertension was 41%.Among the patients with right ventricular dysfunction, 11.2% required a second vasopressor drug for hemodynamic support, and the most frequent complication was atrial fibrillation (33.7%).The requirement for ECMO (Extracorporeal Membrane Oxygenation) in patients with and without right ventricular dysfunction was 3.7% and 2.6%, respectively.The 30-day mortality in patients with right ventricular dysfunction was 8.7% vs. 7.8% in those without right ventricular dysfunction.Conclusions: Postoperative complications and short-term mortality could be similar among patients with or without right ventricular dysfunction who undergo mitral valve replacement surgery.